Cargando…

Linagliptin use in older individuals with type 2 diabetes

Older people have the highest prevalence of type 2 diabetes mellitus (T2DM) of any age group and are thus frequent users of glucose-lowering agents. Because individuals 65 years or older are underrepresented in clinical studies, there is a lack of information regarding the efficacy and safety of ava...

Descripción completa

Detalles Bibliográficos
Autor principal:	Pratley, Richard E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2014
Materias:	Short Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4108453/ https://www.ncbi.nlm.nih.gov/pubmed/25083132 http://dx.doi.org/10.2147/CIA.S62877

Ejemplares similares

Linagliptin improves endothelial function in patients with type 2 diabetes: A randomized study of linagliptin effectiveness on endothelial function
por: Shigiyama, Fumika, et al.
Publicado: (2016)

Cardiovascular outcomes and safety with linagliptin, a dipeptidyl peptidase‐4 inhibitor, compared with the sulphonylurea glimepiride in older people with type 2 diabetes: A subgroup analysis of the randomized CAROLINA trial
por: Espeland, Mark A., et al.
Publicado: (2020)

Linagliptin: farmacology, efficacy and safety in type 2 diabetes treatment
por: Guedes, Erika Paniago, et al.
Publicado: (2013)

Combination of Linagliptin and Metformin for the Treatment of Patients with Type 2 Diabetes
por: Haak, Thomas
Publicado: (2015)

Linagliptin as add-on therapy to insulin for patients with type 2 diabetes
por: von Websky, Karoline, et al.
Publicado: (2013)

Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes
por: Gallwitz, Baptist
Publicado: (2013)

Population Pharmacokinetics and Pharmacodynamics of Linagliptin in Patients with Type 2 Diabetes Mellitus
por: Retlich, Silke, et al.
Publicado: (2015)

Empagliflozin/linagliptin: Euglycaemic diabetic ketoacidosis: case report
Publicado: (2021)

Prototype of an evidence‐based tool to aid individualized treatment for type 2 diabetes
por: Buse, John B., et al.
Publicado: (2021)

Linagliptin—A Novel Dipeptidyl Peptidase Inhibitor for Type 2 Diabetes Therapy
por: Gallwitz, Baptist
Publicado: (2012)

Effects of Linagliptin on Pancreatic α Cells of Type 1 Diabetic Mice
por: Zhang, Yanqing, et al.
Publicado: (2017)

Effect of Switching from Linagliptin to Teneligliptin Dipeptidyl Peptidase-4 Inhibitors in Older Patients with Type 2 Diabetes Mellitus
por: Han, Eugene, et al.
Publicado: (2020)

Neuroprotective effects of linagliptin in a rotenone-induced rat model of Parkinson's disease
por: Abhangi, Kinjal V, et al.
Publicado: (2022)

Acute Kidney Injury Associated with Linagliptin
por: Nandikanti, Deepak K., et al.
Publicado: (2016)

Linagliptin treatment in subjects with type 2 diabetes with and without mild-to-moderate renal impairment
por: Groop, P-H, et al.
Publicado: (2014)

Potential role of linagliptin as an oral once-daily treatment for patients with type 2 diabetes
por: Hoimark, Lene, et al.
Publicado: (2012)

Management of patients with type 2 diabetes and mild/moderate renal impairment: profile of linagliptin
por: Gallwitz, Baptist
Publicado: (2015)

Effects of Linagliptin and Pioglitazone on Fracture Healing in an Experimental Type 2 Diabetes Rat Model
por: Mraja, Hamisi M, et al.
Publicado: (2022)

Testing the Therapeutic Equivalence of Alogliptin, Linagliptin, Saxagliptin, Sitagliptin or Vildagliptin as Monotherapy or in Combination with Metformin in Patients with Type 2 Diabetes
por: Messori, Andrea, et al.
Publicado: (2014)

Clinical utility and tolerability of linagliptin in diabetic patients
por: Maxwell, Lauralee Gordon, et al.
Publicado: (2013)

Use of Canagliflozin in Combination With and Compared to Incretin-Based Therapies in Type 2 Diabetes
por: Pratley, Richard E., et al.
Publicado: (2017)

Initial combination therapy for patients with type 2 diabetes mellitus: considerations for metformin plus linagliptin
por: Freeman, Jeffrey S
Publicado: (2013)

Efficacy of dipeptidyl peptidase-4 inhibitor linagliptin in patients with type 2 diabetes undergoing hemodialysis
por: Terawaki, Yuichi, et al.
Publicado: (2015)

Comparison of adherence and persistence among adults with type 2 diabetes mellitus initiating saxagliptin or linagliptin
por: Farr, Amanda M, et al.
Publicado: (2016)

Linagliptin Lowers Albuminuria on Top of Recommended Standard Treatment in Patients With Type 2 Diabetes and Renal Dysfunction
por: Groop, Per-Henrik, et al.
Publicado: (2013)

Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA(®))
por: Marx, Nikolaus, et al.
Publicado: (2015)

Linagliptin Increases Incretin Levels, Lowers Glucagon, and Improves Glycemic Control in Type 2 Diabetes Mellitus
por: Rauch, Thomas, et al.
Publicado: (2012)

Pharmacokinetic and pharmacodynamic evaluation of linagliptin for the treatment of type 2 diabetes mellitus, with consideration of Asian patient populations
por: Ceriello, Antonio, et al.
Publicado: (2016)

Linagliptin and cardiovascular outcomes in type 2 diabetes after acute coronary syndrome or acute ischemic stroke
por: Li, Yan-Rong, et al.
Publicado: (2018)

The Effect of Linagliptin versus Metformin Treatment-Related Quality of Life in Patients with Type 2 Diabetes Mellitus
por: Mita, Tomoya, et al.
Publicado: (2018)

Preferential prescribing of linagliptin in type 2 diabetes patients in an expanded post‐marketing surveillance study in Japan
por: Fazeli Farsani, Soulmaz, et al.
Publicado: (2019)

Increased leukotriene B4 plasma concentration in type 2 diabetes individuals with cardiovascular autonomic neuropathy
por: Neves, Jose Antonio Januario, et al.
Publicado: (2020)

Treatment of type 2 diabetes in chronic kidney disease: a case for linagliptin in the treatment of diabetes in severe renal impairment
por: Scott, David
Publicado: (2013)

Linagliptin: from bench to bedside
por: Doupis, John
Publicado: (2014)

The clinical application of linagliptin in Asians
por: Cao, Chu-qing, et al.
Publicado: (2015)

Health status of older adults with Type 2 diabetes mellitus after aerobic or resistance training: A randomised trial
por: Ng, Cindy Li Whye, et al.
Publicado: (2011)

Clinical efficacy of linagliptin combined with irbesartan in patients with diabetic nephropathy
por: Liu, Jie, et al.
Publicado: (2022)

Comparison of Adverse Kidney Outcomes With Empagliflozin and Linagliptin Use in Patients With Type 2 Diabetic Patients in a Real-World Setting
por: Lee, Yueh-Ting, et al.
Publicado: (2021)

Oral glucose lowering with linagliptin and metformin compared with linagliptin alone as initial treatment in Asian patients with newly diagnosed type 2 diabetes and marked hyperglycemia: Subgroup analysis of a randomized clinical trial
por: Ma, Ronald CW, et al.
Publicado: (2017)

Effect of empagliflozin versus linagliptin on body composition in Asian patients with type 2 diabetes treated with premixed insulin
por: Zeng, Yi-Hong, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_288a2096mlnso4emgi149iom9q